In our study, we observed that TP53 mutations are highly prevalent in PCa patients and are closely associated with an aggressive cancer phenotype characterized by poor survival and a high recurrence rate, which is consistent with pivotal prior studies. Here, TP53 is linked to posterior cortical atrophy.